Sign In
glob
Find HeartFlow

Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA + FFRCT Precision Pathway is Superior to Traditional Testing

Press Release

Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA + FFRCT Precision Pathway is Superior to Traditional Testing

Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease offers higher diagnostic accuracy, fewer unnecessary tests and higher confidence in identifying patients needing treatment.

MOUNTAIN VIEW, Calif. – November 6, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results that show evaluating stable chest pain patients by applying advanced artificial intelligence (AI) to CCTA increases diagnostic accuracy, reduces unnecessary testing and offers higher confidence in identifying patients needing treatment.

The results from the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) Trial were presented today as late-breaking clinical data at the American Heart Association’s (AHA) Scientific Sessions in Chicago.

“This is the strongest level of scientific evidence yet to support the approach professional guidelines recommend that physicians use to diagnose stable chest pain patients,” said Pamela Douglas, M.D., MACC, FASE, FAHA, the Ursula Geller Professor for Research in Cardiovascular Disease, Duke University School of Medicine and study chair of the PRECISE trial. “Combining multiple steps into a Precision Pathway provides a clear path forward for clinicians.”

PRECISE is the first global randomized controlled trial of its kind, enrolling 2,103 participants at 65 sites. The trial confirms that the CCTA+FFRCT-centered strategy, recognized by the AHA/ACC Guidelines, is the superior diagnostic pathway for patients with stable chest pain and suspected coronary artery disease.

The trial compares a non-invasive Precision Pathway to Traditional Testing which includes stress testing or invasive cardiac catheterization. The Precision Pathway is consistent with the AHA/ACC guideline-recognized approach that defers testing for low-risk chest pain patients and tests all others with CCTA and conditional FFRCT. FFRCT uses human analysis coupled with AI to create an interactive 3D computer model of the heart that quantifies and displays blood flow and blockages.

Compared to Traditional Testing, the PRECISE trial showed that the Precision Pathway:

  1. improved non-invasive diagnostic accuracy, significantly lowering the rates of false negatives and false positives compared to Traditional Testing in patients with coronary artery disease.
  2. reduced unnecessary tests, providing better patient experience and more efficient use of hospital resources with a 4x reduction in unnecessary invasive catheterization and necessitating fewer initial diagnostic tests overall.
  3. increased confidence in treating the right patients – 75% more likely to identify patients in need of intervention.

“We’re pleased to see these data support what the guidelines already recognize,” said Campbell Rogers, MD, FACC, Chief Medical Officer, HeartFlow. “We believe this level-one clinical science information will be used by more practitioners to guide decisions on how to optimize care for people with suspected coronary artery disease.”

A CCTA + FFRCT pathway has been adopted by more than 725 hospitals worldwide, including 80% of the Top 50 Heart Hospitals in the US.

###

About HeartFlow

HeartFlow is the global leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced AI technology. Headquartered in Mountain View, California, our technology has been published in more than 500 peer-reviewed publications that showcase the value of anatomy, physiology, and plaque. We began our journey to improve coronary artery disease (CAD) diagnosis with FFRCT and have now expanded our product portfolio to include anatomic stenosis and plaque information. To date, clinicians have used our technology for more than 135,000 patients to aid in the diagnosis of heart disease.1 For more information, visit www.heartflow.com and connect on Twitter and LinkedIn.

Contact

Linly Ku
HeartFlow
media@heartflow.com

  1. Data on file at HeartFlow
cert logo hitrust.7394f2b.cda83af2e008d8cc68f55103dbde7712

HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.

© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041

173961476 v1

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます！

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.